melanoma
The position of the mutations and the loss of heterozygosity of MAP3K5 and MAP3K9 in 85% and 67% of melanoma samples, respectively, together suggest that the mutations are likely to be inactivating.
The position of the mutations and the loss of heterozygosity of <span class="gene" id="22197930-4-64-70">MAP3K5</span> and MAP3K9 in 85% and 67% of <span class="disease" id="22197930-4-100-108">melanoma</span> samples, respectively, together suggest that the mutations are likely to be inactivating.